Physicians

Department / Division
Medicine / Medicine - Cell Therapy and Hematologica

Address
DUMC 3961
Durham, NC 27710

Appointment Telephone
919-668-1027

Office Telephone
919-668-1040

Fax Telephone
919-668-1091

Training

• MD, University of Rochester School of Medicine and Dentistry (New York), 1991

Residency

• Internal Medicine, Strong Memorial Hospital, University of Rochester Medical Center (New York), 1991-1994

Fellowship

• Hematology and Oncology, Duke University Medical Center, 1994-1997

Clinical Interests
Bone-marrow and stem-cell transplantation; manipulation of minimal residual disease in patients with hematologic malignancies (lymphoma, leukemia); phase 1 trials for leukemia and lymphoma

Research Interests
My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease. Recent endeavors have included:
1) Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways
2) New monoclonal antibodies targeting tumor stroma rather than cellular antigens
3) Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies
4) Aggressive therapy and transplantation for mantle cell lymphoma
5) Antiangiogenesis therapy for patients with NHL
6) Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Allos
• CTI pharma
• Celgene Corporation
• GlaxoSmithKline
• Novartis
• Pfizer Inc.
• Sanofi-Aventis
• Spectrum Laboratories
• Teva Pharmaceuticals
• incyte
• seattle genetics

Representative Publications
Rao, AV; Akabani, G; Rizzieri, DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clinical Medicine and Research. 2005;3:157-165. (2005) Abstract

Shanks, RH; Rizzieri, DA; Flowers, JL; Colvin, OM; Adams, DJ. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clinical Cancer Research. 2005;11:4225-4233. (2005) Abstract

Bhagat, R; Rizzieri, DA; Vredenburgh, JJ; Chao, NJ; Folz, RJ. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?. Chest. 2004;126:642-644. (2004) Abstract

Chao, NJ; Koh, LP; Long, GD; Gasparetto, C; Horwitz, M; Morris, A; Lassiter, M; Sullivan, KM; Rizzieri, DA. Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biology of Blood and Marrow Transplantation. 2004;10:569-575. (2004) Abstract

Rizzieri, DA; Akabani, G; Zalutsky, MR; Coleman, RE; Metzler, SD; Bowsher, JE; Toaso, B; Anderson, E; Lagoo, A; Clayton, S; Pegram, CN; Moore, JO; Gockerman, JP; DeCastro, C; Gasparetto, C; Chao, NJ; Bigner, DD. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004;104:642-648. (2004) Abstract

Rizzieri, DA; Johnson, JL; Niedzwiecki, D; Lee, EJ; Vardiman, JW; Powell, BL; Barcos, M; Bloomfield, CD; Schiffer, CA; Peterson, BA; Canellos, GP; Larson, RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438-1448. (2004) Abstract

Rizzieri, DA; Sand, GJ; McGaughey, D; Moore, JO; DeCastro, C; Chao, NJ; Vredenburgh, JJ; Gasparetto, C; Long, GD; Anderson, E; Foster, T; Toaso, B; Adams, D; Niedzwiecki, D; Gockerman, JP. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004;100:2408-2414. (2004) Abstract

Snyder, MJ; Stenzel, TT; Buckley, PJ; Lagoo, AS; Rizzieri, DA; Gasparetto, C; Vredenburgh, JJ; Chao, NJ; Gong, JZ. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. American Journal of Surgical Pathology. 2004;28:794-800. (2004) Abstract

Talbot, J; Ibom, VK; Rizzieri, DA; Barrier, R; Niedzwieki, D; DeCastro, CM; Moore, JO; Buckley, P; Laney, R; Stevenson, D; Rumbaugh, H; Gockerman, JP. Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. Clinical Lymphoma and Myeloma. 2004;5:116-122. (2004) Abstract

Gong, JZ; Stenzel, TT; Bennett, ER; Lagoo, AS; Dunphy, CH; Moore, JO; Rizzieri, DA; Tepperberg, JH; Papenhausen, P; Buckley, PJ. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. American Journal of Surgical Pathology. 2003;27:818-827. (2003) Abstract

Ibom, VK; Prosnitz, RG; Gong, JZ; Moore, JO; DeCastro, CM; Prosnitz, LR; Rizzieri, DA; Gockerman, JP. Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Clinical Lymphoma and Myeloma. 2003;4:115-118. (2003) Abstract

Rizzieri, DA; Ibom, VK; Moore, JO; DeCastro, CM; Rosner, GL; Adams, DJ; Foster, T; Payne, N; Thompson, M; Vredenburgh, JJ; Gasparetto, C; Long, GD; Chao, NJ; Gockerman, JP. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clinical Cancer Research. 2003;9:663-668. (2003) Abstract

Rizzieri, DA; Talbot, JT; Long, GD; Vredenburgh, JJ; Gasparetto, C; Smith, CS; Colvin, MO; Adams, D; Morris, A; Dodge, R; Loftis, J; Waters-Pick, B; Reese, M; Carawan, H; Koh, LP; Chao, NJ. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. Biology of Blood and Marrow Transplantation. 2003;9:183-188. (2003) Abstract

Talbot, J; Rizzieri, DA; DeCastro, CM; Moore, JO; Buckley, P; Laney, R; Stevenson, D; Brumbaugh, H; Gockerman, JP. High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series. American Journal of Hematology. 2003;73:295-296. (2003) Abstract

Bass, AJ; Gockerman, JP; Hammett, E; DeCastro, CM; Adams, DJ; Rosner, GL; Payne, N; Davis, P; Foster, T; Moore, JO; Rizzieri, DA. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. Journal of Clinical Oncology. 2002;20:2995-3000. (2002) Abstract

Bass, AJ; Gong, J; Nelson, R; Rizzieri, DA. CD52 expression in mantle cell lymphoma. Leukemia and Lymphoma. 2002;43:339-342. (2002) Abstract

Chao, NJ; Liu, CX; Rooney, B; Chen, BJ; Long, GD; Vredenburgh, JJ; Morris, A; Gasparetto, C; Rizzieri, DA. Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biology of Blood and Marrow Transplantation. 2002;8:249-256. (2002) Abstract

Gasparetto, C; Gasparetto, M; Morse, M; Rooney, B; Vredenburgh, JJ; Long, GD; Rizzieri, DA; Loftis, J; Chao, NJ; Smith, C. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine. 2002;18:8-19. (2002) Abstract

McCune, SL; Gockerman, JP; Moore, JO; Decastro, CM; Bass, AJ; Chao, NJ; Long, GD; Vredenburgh, JJ; Gasparetto, C; Adams, D; Payne, N; Rizzieri, DA. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leukemia and Lymphoma. 2002;43:1007-1011. (2002) Abstract

Rizzieri, DA; Bass, AJ; Rosner, GL; Gockerman, JP; DeCastro, CM; Petros, WP; Adams, DJ; Laughlin, MJ; Davis, P; Foster, T; Jacobson, R; Hurwitz, H; Moore, JO. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. Journal of Clinical Oncology. 2002;20:674-679. (2002) Abstract

Guzman, ML; Neering, SJ; Upchurch, D; Grimes, B; Howard, DS; Rizzieri, DA; Luger, SM; Jordan, CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307. (2001) Abstract

Guzman, ML; Upchurch, D; Grimes, B; Howard, DS; Rizzieri, DA; Luger, SM; Phillips, GL; Jordan, CT. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001;97:2177-2179. (2001) Abstract

Laughlin, MJ; Barker, J; Bambach, B; Koc, ON; Rizzieri, DA; Wagner, JE; Gerson, SL; Lazarus, HM; Cairo, M; Stevens, CE; Rubinstein, P; Kurtzberg, J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New England Journal of Medicine. 2001;344:1815-1822. (2001) Abstract

McCune, SL; Gockerman, JP; Rizzieri, DA. Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. JAMA: Journal of the American Medical Association. 2001;286:1149-1152. (2001) Abstract

Rizzieri, DA; Long, GD; Vredenburgh, JJ; Gasparetto, C; Morris, A; Stenzel, TT; Davis, P; Chao, NJ. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood. 2001;98:3486-3488. (2001) Abstract

Elconin, JH; Roberts, KB; Rizzieri, DA; Vermont, C; Clough, RW; Kim, C; Dodge, RK; Prosnitz, LR. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal of Radiation: Oncology - Biology - Physics. 2000;48:1097-1105. (2000) Abstract

Jordan, CT; Upchurch, D; Szilvassy, SJ; Guzman, ML; Howard, DS; Pettigrew, AL; Meyerrose, T; Rossi, R; Grimes, B; Rizzieri, DA; Luger, SM; Phillips, GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784. (2000) Abstract

Rizzieri, DA; Vredenburgh, JJ; Jones, R; Ross, M; Shpall, EJ; Hussein, A; Broadwater, G; Berry, D; Petros, WP; Gilbert, C; Affronti, ML; Coniglio, D; Rubin, P; Elkordy, M; Long, GD; Chao, NJ; Peters, WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. Journal of Clinical Oncology. 1999;17:3064-3074. (1999) Abstract

Laughlin, MJ; Rizzieri, DA; Smith, CA; Moore, JO; Lilly, S; McGaughey, D; Martin, P; Carrier, C; Stevens, CE; Rubinstein, P; Buckley, R; Kurtzberg, J. Hematologic engraftment and reconstitution of immune function post unrelated placental cord blood transplant in an adult with acute lymphocytic leukemia. Leukemia Research: clinical and laboratory studies. 1998;22:215-219. (1998) Abstract

Rizzieri, DA; Chao, NJ. Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support. Current Opinion in Oncology. 1997;9:420-427. (1997) Abstract

Rizzieri, DA; Liu, J; Miralles, D; Traweek, ST. Kaposi's-sarcoma-associated herpesvirus is detected in peripheral blood mononuclear cells of HIV-infected homosexuals more often than in heterosexuals. Cancer Journal from Scientific American. 1997;3:153-156. (1997) Abstract

Rizzieri, DA; Liu, J; Traweek, ST; Miralles, GD. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor. Lancet. 1997;349:775-776. (1997) Abstract

Rizzieri, DA; Wong, WM; Gockerman, JP. Thrombocytosis associated with low-molecular-weight heparin. Annals of Internal Medicine. 1996;125:157. (1996) Abstract

Rizzieri, DA. Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia. Mayo Clinic Proceedings. 1995;70:473-476. (1995) Abstract